Phenoxybenzamine Shortage Update: What Patients Need to Know in 2026

If you have been prescribed phenoxybenzamine and are struggling to fill it, you are not alone — and you are not overreacting. Phenoxybenzamine has historically been one of the most difficult medications to locate at a retail pharmacy, and the situation has not significantly improved heading into 2026. Here is what you need to know about the current availability picture.

Is Phenoxybenzamine on the FDA Shortage List in 2026?

As of early 2026, phenoxybenzamine is not listed as an active shortage on the FDA Drug Shortages Database. This might sound reassuring, but for a drug with this unique supply profile, the absence of an official FDA shortage designation does not mean it is easy to find.

The FDA typically tracks shortages for drugs that serve large patient populations and have widespread clinical impact when unavailable. Phenoxybenzamine treats pheochromocytoma, which affects an estimated 500 to 1,000 patients annually in the United States. Because the absolute number of patients is small, pharmacy-level unavailability does not usually trigger an FDA shortage designation — but it absolutely disrupts the individual patients who need it.

International Shortage: Australia as a Warning Sign

In Australia, the picture is clearer. The brand Dibenzyline (phenoxybenzamine hydrochloride 10 mg capsules) was listed on the Therapeutic Goods Administration (TGA) Medicine Shortages database as unavailable in 2025 and into 2026, with an expected supply date pushed to mid-2026. Australian authorities approved an unregistered alternative product for supply under emergency provisions, highlighting just how fragile the supply chain for this niche drug is.

While the Australian shortage does not directly affect U.S. patients, it illustrates how quickly supply can fail for a low-volume drug when manufacturing or distribution issues arise. Phenoxybenzamine has a single-digit number of manufacturers worldwide, meaning disruption at any one point in the supply chain can quickly cascade into broad unavailability.

Why Phenoxybenzamine Is Structurally Hard to Find

Availability challenges for phenoxybenzamine are not simply a temporary disruption — they are structural features of how this drug is manufactured and distributed:

Tiny patient population: Pheochromocytoma is a rare condition. Low overall demand means most pharmacies have no financial incentive to stock phenoxybenzamine.

Very high cost: Retail prices exceed $6,700 for a 30-day supply at standard pharmacies. Pharmacies are reluctant to hold expensive inventory for a drug with minimal turnover.

Short-term use: Phenoxybenzamine is typically used for only 1 to 4 weeks prior to surgery, so patients are not recurring customers. This further reduces the pharmacy's motivation to maintain stock.

Limited manufacturers: Phenoxybenzamine is made by a very small number of manufacturers globally (ANI Pharmaceuticals for the generic in the U.S.), making the supply chain vulnerable.

What Patients Should Do Right Now

If you have been prescribed phenoxybenzamine, the most important thing you can do is act immediately. Waiting to fill the prescription can delay your surgery. Here is a practical action plan:

Call your prescribing physician the same day. Ask which pharmacy they recommend for phenoxybenzamine. Many endocrine surgeons and endocrinologists know exactly where to direct patients.

Contact the hospital outpatient pharmacy. If your surgery is at a major medical center, their pharmacy often stocks phenoxybenzamine for outpatient use.

Call specialty pharmacies. Pharmacies that specialize in oncology or rare diseases are more likely to carry or quickly order phenoxybenzamine.

Use medfinder. medfinder calls pharmacies near you to check phenoxybenzamine availability and texts you the results, eliminating the need to make dozens of calls yourself.

Ask your doctor about alternatives. If phenoxybenzamine cannot be located within a day or two, request a switch to doxazosin. Clinical evidence supports it as a viable alternative and it is available at every pharmacy.

Looking Ahead: Will Phenoxybenzamine Availability Improve?

There is no indication that the structural challenges limiting phenoxybenzamine availability will resolve in the near term. The small patient population, high price, and limited manufacturer base are features of this drug's market that are unlikely to change significantly. The increasing adoption of doxazosin and other selective alpha-1 blockers as primary agents for pheochromocytoma management may actually reduce demand for phenoxybenzamine further over time.

For patients who do need phenoxybenzamine, having a reliable search strategy — including medfinder — is more important than ever. Do not rely on walking into a random pharmacy and expecting to find it on the shelf.

Learn more about your options: Alternatives to Phenoxybenzamine If You Can't Fill Your Prescription.